

DISCLOSURE


I am currently an employee of AstraZeneca; however, the presentation and opinions expressed today are solely mine and do not represent my current or any past employer.

The LungAmbition Alliance









LEARN FROM MY EXPERIENCE...

Taking short cuts or missing a step has consequences

THE RIGHT STEPS REALLY DO MATTER!



PROGRAM TRANSFORMATION JOURNEY

Phase 1	Phase 2	Phase 3	Phase 4
Discovery & Needs Assessment	Planning	Execution & Implementation	Optimization

MY 10 STEPS

Step 1	Step 2	Step 3	Step 4	Step 5	
Identifying Program Champion	Determine Program Infrastructure	Resource Assignment	Barriers Assessment	Advocacy & State Coalition Engagement	
Step 6	Step 7	Step 8	Step 9	Step 10	
Program Model	Workflow Protocol & Clinical Pathways	Tools & Outreach Planning	Roll-out Plan	Assess, optimize, scale	

PROGRAM TRANSFORMATION JOURNEY

Phase 1 | Discovery & Needs Assessment
Phase 2 | Planning

Phase 3 | Execution & Implementation

Phase 4 | Optimization & Support

Step 1	Step 2	Step 3	Step 4	Step 5	
Program Champion	Program Infrastructure	Resource Assignment	Barriers Assessment	Advocacy & State Coalition Engagement	
Step 6	Step 7	Step 8	Step 9	Step 10	
Program Model	Workflow Protocol & Clinical Pathways	Tools & Outreach Planning	Roll-out Plan	Assess, optimize, scale	


FAILING TO PLAN

=
PLANNING TO FAIL



LCS VERSES IPN PROGRAM

 Screening is complex with many touchpoints



Incidental less complex




Where do I start?

STEP 1

☐ Identify physician champion



- ☐ Determine Program Infrastructure
- ✓ Map out organizational chart
- Develop a formal program charter with roles, responsibilities, program autonomy
- ✓ Consider SWOT or SBAR analysis
- ✓ Write job descriptions
- ✓ Form Implementation workgroup:
 - Clinical stakeholders
 - Lead Physician Champion
 - Program Navigator
 - Radiologist
 - Pulmonologist
 - Thoracic Surgeon
 - Primary Care
 - Administrative leader
 - Compliance & Legal
 - Radiology
 - Marketing
 - Physician Relations
 - Registration
 - Scheduling
 - Revenue Integrity/Billing/Coding



- ☐ Resource Assignment
- ✓ Identify program lead
- ✓ Plan and assign staffing resources



- ☐ Barriers Assessment
- Identify internal and external barriers
- ✓ Develop mitigation strategy
- Build your program around your findings







- Advocacy & State Coalition Engagement
- ✓ Indigent care
- ✓ ROI calculators
- ✓ Start up resources
- ✓ State cancer goals



GEORGIA CANCER CONTROL





- ☐ Program Model
- Determine program model.PCP or Program managed?

Note: If building IPN program, determine filtering criteria


- ❖ Which exams?
- EMR or software capabilities for search criteria? Can it easily be refined to minimize false positives & undesired cases? (i.e., complex cancer or nodule follow up.)
- Patient type/departments?
- Age criteria?
- Ordering physician?
- Ordering indication?




- ☐ Workflow Protocol & Clinical Pathways
- ✓ Develop & map out <u>Nodule</u>
 <u>Management & Clinical Workflow</u>
 <u>Protocol</u> (Applies to both LCS & IPN)
- Explore and compare software options for patient management and data tracking

Note: The workflow will differ for IPN program.

- Must address <6mm NCN for those who don't meet Fleischner criteria. You basically have 6 options.
 - 1. Do nothing
 - 2. Manage through program
 - 3. Manage through clinical trial
 - 4. Manage though blood assay testing
 - 5. Defer to PCP but send patient notification
 - 6. Defer until system has a plan nothing needed sooner than 12 months anyway
- Remember these patients are unaware unlike LCS. You will be notifying them retrospectively. Must factor this into the notification process.



- ☐ Tools & Outreach Planning
- Develop program support tools, materials, and plans
- 1) Forms & Documents
 - Notification letters
 - Intake forms
 - Orders/referrals
 - Workflow process/algorithm
 - Dictation template
 - Schedule call script
 - Program Charter
- 2) Smoking Cessation Integration Plan
- 3) Marketing & Community Outreach
 - Collateral Materials
 - Marketing & Outreach Plan
 - Physician & community Education
- ACR Registry & COE Screening Designation Application
- 5) Finalize plan for software or patient management and data tracking tools



SCREENING INTAKE FORMS

Addresses Research Registry, smoking cessation, and serves as consent to multi-disciplinary review process

	er Screening	WELLSTAR.	Lung Screening Hi		EALTH & BACKGE	ROUND HISTORY	Page
History Assessment			Is this your first lung o		Have you taken When?	any antibiotics wi For Wh	thin the past 6 months? No Yes
EASE PRINT CLEARL	Y			riencing any of the follow		101	If yes, please explain
ame(Last)	(First) (MI)	Date of Sixth Age Gonder / / Male Decade		cough, coughing up bloo		No Yes	ir yes, presse exposit
forme Phone	Work Phone	Cell Phone	Do you have a family hi	istory of lung cancer?		No Yes	If yes, please list family member(s)
taling Address	· ·		cancer causing or conc			No Yes	If yes, please explain
Smary Care Ductor <u>- FIRST</u> & LA	ST Name Street Address City	State Zip	maintenance, mining, c	y of these industries; au construction, demolition, epair? No LY	nuclear power, as	l, foundry, refinery chestos product ma	r, building if yes, please explain mufacturing,
f you would like a copy of your res	ults sent to a pulmouologist, please write FIRST & LAST Name and	address		ck, abdominal or chest s			
f you would like a copy of your res	ults sent to a cardiologist, piezze write PIRST & LAST Name and ac	dress	No Yes	Cancer Type:		nosed when?	How was It treated?
			□No □Yes	Asthma			
Decupation	How did you hear about lung cancer accessing?	Ernall Address	No Yes	Emphysema			
			■No ■Yes	COPD or Pulmonary			
surs of Education		Served in the military? (If yes, what branch?):	■ No ■ Yes	High Blood Pressure			
Les Destarrantes	ese/trade school = Underwaduste = Udvanced deuree	□No □Yes	No Yes	High Cholesterol Diabetes			
let 2 Ut 2 (or GED) 2 vr cell		Hispanic/Latino Other	No Yes	Heart Attack, Angiop	lasty, Heart Steat	or Heart Surperv	
Concae An	WHAT YOU NEED TO KNOW	grispanic/Latino Societ	2			OKING EXPOSURE	
	Please read below and sign		Please shock one:				
			Preuse check one: Cur	rent Smoker 🔲 Former	Smoker Meve	r Smoker (smoked	less than 100 cigarettes in your lifeting
est can detect tiny nodules in the	one-time exam, but a process that involves periodic follow-up CT - lungs that are too small to be seen on a chest a-cay. The capa	afility of CT scanners to detect these tiny nedules and to	If never smoker, how n	nany years exposed to se	condhand smoke?	?	_
rempare for changes in size over ti	ine is critical to the screening process. Research shows low-dose t	T screening is effective in reducing lung cancer deaths.	How old were you whe	n you first started Wh	ich tehacce produ	cts would you resu	larly use - either in the past or now?
like most medical procedures, scr	senings have inherent risks and limitations. Considering the lifetir	ne probability of developing lung cancer is 1 in 14 people,	smoking?			Pipes 🔲 🗆	
	rate is 1-5%, the risks of acreening through an organized acreening one of screening include: This test may find absormalities				Ligarettes L	pripes u.c.	igars Dother
sbnormalities can lead to addition	ral tests and cause anxiety. Tests rould include repeat CT scans	or more invasive procedures such as a broachescopy or	How many packs of cig used to smoke per day		16-1	ipe, # of loads	_# of CigarsOther
expesse you to less than 1.5 millists	can lead to complications like a collapsed lung or, rarely, even de- worts [m5v] of radiation. This is much less radiation than a conve	ntional chest CT scan, which would expose you to about 7	used to smoke per day.		n p	ipe, a or ioaus	or cigarsouer
10 mSv. Evidence suggests that	the risk of cancer caused by this test is very low. Harm can co much higher than necessary levels of radiation - another reason	me is the form of improperly performed CT scans that	How many years have	you or Have you since	e quit, if so, when?	Are you cur	rrently trying to quit smoking?
experienced site that adheres to a	well-defined protocol for acreening. This test may not detect all	lung cancers and is no guarantee early detection will	did you smoke?				
bund early, and spread to other p.	early Increases your chance for survival through early treatment arts of the body. This is called metastasis. Once a cancer has sprea	and cure; however, some cancers can recur, even when d. It is difficult to treat and often leads to death. Research		■No ■Ye	s	-	No Yes
continues to show early detection	is the best hope for survival.		If YES, and are ready to	quit tobacco, please indi	cate with your init	tals that you would	like to be contacted by a Georgia Toba
below indicates you authorize ti	ing process, a multi-disciplinary review by our Lung Caucer Scre his team of disctors with special training and expertise in h sabilished screening protocol. These physicians are committed to fe	ng cancer acrossing to review your exam and make	Quit Line counselor. Thi Regarding smoking cess	is is a Free resource provi sation	ding counseling, se	upport and referral	for all Georgia residents 18 years and a
recommendations tonowing an est and unnecessary levasive procedu	res.	stowing nest published practices to avenue over-treatment	(Initial) Plea:	sa have the Georgia Toho	con Quit Line contr	net ma to haln ma w	rith my quit plan. I give permission for s
I adoptiveledge, understand and as	ree that my CT examination report will be maded to my and my	primary physician listed above. The report may contain					tobacco counselor to call me between ti
Information that is protected unde	yee that my CT examination report will be mailed to my and my c State law and Federal regulations and WellStar Health System is	not liable or responsible should the report and/or images	hours indicated. If I am	unavailable, the counsels	or may leave a mes	sage. Best time to c	rall:
Cancer Screening Decision Making	t is my responsibility to follow up with my doctor regarding the r Guide and Research Registry Information Sheet and all questions	sealts of this easen. I have been given a copy of the Lung I have regarding this easenlastion have been adequately	□ 6.	AM-9AM 🔲 9AM-1:	2PM 12PM	-3PM 🔲 3PM-6	5PM □ 6PM-9PM
suswered. I understand that I may	withdraw my participation at any time.		WELLSTAR STAFF USE - IM	PORTANT: Please remembe	rt .		
			1) Scan this documen	st to Media Tab and label LCS I g department at 470-793-4243	ntake	secon or order	
Signature:		Date:	.,	,,			
levised 05/2018			Revised 05/2018				
		Affix Patient Label Here					
		l l					
	Harris and the same and the same and the	Have very stone muit if an order	-0			a a luina mO	
	How many years have you or did	Have you since quit, if so, whe	n? Are yo	ou currently tryin	ig to quit sit	ioking?	
1	you smoke?	□ No □ Yes	IΠN	lo Nes			
ı	,	U 100					
-	Maria and an analysis and a		41-4	the control of		T-1	
		co, please indicate with your initials					
in I	This is a free resource providing of	ounseling, support, and referral for	all Georgia residents	18 years and old	der regardin	ng smokina d	cessation.
·	(Initial) Please have	the Georgia Tobacco Quit Line cont	act me to neip with m	y quit piari. I giv	e permissio	iii ioi iiiy hai	ine, age, city, and
I.	phone number listed above to be _l	provided to the Quit Line and for a t	obacco counselor to c	all me between	the hours it	ndicated. If I	am unavailable, the
1	counselor may leave a message.	Best time to call:					
- 1	,	4 40 DM		□ a pr :			

MELLI STAD STAFFLISE IMPODIANT: Diago remember

First healthcare organization in Georgia!

Research Registry Information Sheet Sponsor: WellStar Health System

Protocol Title: Lung Screening Research Registry

Principal Investigator: Robert Hermann, M.D., F.A.C.P.

Co-Investigators: Vickie J. Beckler, R.N., Aaron Cann, M.D., Ph.D., William R. Mayfield, M.D., Introduction and Purpose

LUNG CANCER SCREENING

To advance research and help broaden

RESEARCH REGISTRY &

PROTOCOL

screening criteria

You are being asked to be in a research registry that will collect and securely store data in a confidential concernor expension detabase because more research is needed to help define and identify. rou are being asked to be in a research registry that will collect and securely store data in a confidential cancer screening database because more research is needed to help define and identify Cancer trends and outcomes in various at-risk po

- Morphology and progression of lung and heart di Benefits of screening various at-risk populations

The National Lung Screening Trial (NLST) was limited or 55-74 with a 30 pack year smoking history or had quit w of people continue to die each year from lung cancer tha the population remain at risk and are current

Community-Based Multidisciplinary Computed Tomography Screening Program Improves Lung Cancer Survival

Daniel L. Miller, MD, William R. Mayfield, MD, Theresa D. Luu, MD, Gerald A. Helms, MD, Alan R. Muster, MD, Vickie J. Beckler, BSN, and Aaron Cann, MD, PhD

Multidisciplinary Thoracic Oncology Program, WellStar Health System/Mayo Clinic Care Network, Marietta, Georgia

Background. Lung cancer is the most common cause of cancer deaths in the United States. Overall survival is less than 20%, with the majority of patients presenting with advanced disease. The National Lung Screening Trial, performed mainly in academic medical

pulmonary nodules were found in 518 patients (41%). Thirty-six patients (2.8%) underwent a diagnostic procedure for positive findings on their CT scan; 30 proved to have cancer, 28 (2.2%) primary lung cancer and 2 metastatic cancer, and 6 had benign disease. Fourteen

LUNG SCREENING RESEARCH REGISTRY PROTOCOL

WellStar Health System c/o Lung Screening Program 522 North Ave Marietta, Georgia 30060 678-594-4302

Principal Investigator: Robert Hermann, M.D., F.A.C.S.

$c_{o ext{-}Investigators:}$

Vickie J. Beckler, R.N. Aaron Cann, M.D., Ph.D. William R. Mayfield, M.D. Alan R. Muster, M.D.

- Roll-out Plan
- Develop roll out strategy using a phased approach.
- With all prior steps complete, launch program using small group as an initial pilot

Lung Cancer Screening Launch Plan

Phase 1 | Soft Go-Live May 1-30, 2021

30-day Internal Employee Roll-out

- Employee recruitment
- Newsletters
- Paystubs
- Email blast
- Intranet Page

Phase 2 | Community Pilot June 1-August 31, 2021

90-day community screening pilot with top 1-2 physician groups or practices

- ABC Primary Care Group
- Dr. A
- Dr. B
- Dr. C
- 6/1-8/31 Screen referred patients and follow proposed Workflow Protocol • 9/1-9/30
- Evaluate workflow effectiveness
- Regroup with key stakeholders
- Review progress & outcomes
- Edit/modify workflow and processes as

Phase 3 | Official Launch October 1, 2021

Roll-out to all practices

- 10/1-12/31 = Schedule PCP & pulmonary site visits with physician liaisons to educate and deliver
- 10/1-11/30 = Leverage ground rounds, breakrooms to educate
- 10/1-12/31 = Direct mail campaign
- 10/1-12/31 = Leverage marketing & outreach opportunities: magazines, advertisements, screen savers, etc.,

3, grow, and win BIG!

- Assess, Optimize, Scale
- Upon completion of initial pilot, assess effectiveness, modify or adjust Nodule Management & Clinical Workflow Protocol as needed



COMPONENTS TO SUCCESS

- Growth & sustainability
- The Patient Journey

GROWTH & SUSTAINABILITY

Obstacles

- Lack of leadership support or engagement of critical stakeholders
- Lack of system funding
- No dedicated navigator or one with no autonomy to lead
- No defined or standardized clinical workflow
- Inefficient and ineffective workflow
- Poor patient management practices
- Poor patient screening adherence
- System deployed siloed screening programs
- Overcomplicate shared decision making (SDM)

Drivers

- Engagement & Support
 - Support from senior leadership and PCP engagement
 - Dedicated physician review team and champion with program oversight
 - Program navigator with autonomy to lead
 - Screening Triad: Nurse Navigation, MDC Team, COE Designated
- Education
 - Invest time up front building physician & patient relationships
 - Navigator & Champion should be the "Face of Screening"
 - Improves confidence, referrals, and adherence
 - Patients who understand the survival benefit are more inclined to adhere to continued screening
- Effective & efficient service delivery processes
 - Make it easy for ordering clinician and patient
 - One Stop approach to screening
 - One-call, one-time scheduling
 - Communicate results & recommendations promptly and directly to both patient and ordering clinician
 - Manage nodules through program– helps to minimize overtreatment through protocol adherence
 - Program navigate the patient
 - Program schedules the follow-up
 - Effective patient management platform or software
 - Own the process all touchpoints in-house!
 - Implement effective, efficient, AND scalable workflow processes

THE PATIENT JOURNEY


Incorporate Design Thinking (*Human Center Design*) Methodology Into Build

 Process used to understand product end-users, challenge assumptions, redefine problems and create innovative solutions to prototype and test. Incredibly useful to tackle problems that are ill-defined or unknown.

Five phases

- Empathize Put yourself in end-user's shoes. Study to understand how the issue, situation looking to solve makes them feel or the overall impact.
- Define
- Ideate
- Prototype
- Test
- Examples
 - PillPack
 - Airbnb
 - Uber Eats
 - Doug Dietz Transforming MRI Scanners for kids
 - Industrial Engineer GE Health System
 - Great TED talk "Brick wall with a hole in it."
 - His challenge How to create a scanner EXPERIENCE that children would love?





THE PROBLEM WITH BOX THINKING

Inside = Basic, usual, and ordinary

Thought process... "How are others doing this?"




Outside = Proactive, creative & innovative
Thought Process... "How can we do this better?"



USING PATIENT CENTERED DESIGN IN PROGRAM BUILDING

Journey Map & Connect Fundamental Components

- Community Outreach
- Referral Process
- Program Entry
- LDCT Scan Day
- Communication of Results
 & Patient Navigation
- Intervention & Treatment
- Follow-up, Adherence, Data Collection
- Wellness & Survivorship



Lung Screening Process



- *Determine screening guidelines (Only USPSTF or both USPSTF and NCCN
 - ■USPSTF (covered through age 80) by private insurance and age 27 for Medicare)
 - NCCN2 (not covered by private insurance)
- *Marketing to target at-risk population
- *Patient education
- *Provider education



Referral Process

- Clinical Appointment.
- Qualification/Identification of arrisk
- *SDM
 - Risks/Benefits
 - Smoking Conation
- Order



Program Entry

- Order received & eligibility reviewed.
- Pre-certification/coverage determination alnurance or consider offering an affordable self-pay program for those with no insurance, high deductibles. meet NCCN2 criteria or CMS age 78-80
- Parient Scheduled



LD CT Scan Day

- . Patient Welcome & Registration
- · Distribute Intake Assessment
 - Provide education material «Assess readiness to quit
- Exam Completed



Communication of Results & Patient Navigation

- Exam read by radiologist
- Navigator presents results for review by MDC/Nodule Clinic team.
- Navigator disseminates/communicates results to ordering clinician and patient encourage a time goal - for example... 72 hours)
 - · Negative
 - -LungRADS 1 & 2
 - . Via letter with patient return to annual screening on SAME scanner. (Reinforce the importance of annual screening & adherence.)
 - @Positive
 - -LungRADS 3 & 4A
 - Via letter with patient to return for interim 3 or 6 month CT on SAME scanner;
 - . Via phone call followed by letter. If patient feels anxious, have navigator coordinate Nodale Clinic or consult appointment.
 - -LungRADS 4B & 4X
 - . Via phone call with recommendation for a FAST TRACK patient evaluation in Nodule Clinic or appropriate specialist
 - OIf nodule seview team meets weekly, recommend an expedited process where navigator could contact member of physician review team for quick review & guidance. Navigator could then communicate recommendation to ordering clinician and help with patient navigation to EAST TRACK clinic or specialy



Intervention & Treatment (Fast Track Approach)

- Nodule Clinic Evaluation (Consider incorporating a time frame to support prompt work-up, intervention & treatment. For example, time of suspicious exant to diagnosis to treatment less than 30 days and time of suspicious exam to consult for 4X, <72 hours.)
 - ★Treatment Options
 - -Surveillance CT
 - -Biopsy
 - . Pulmonary, IR, verses

Thoracic

ONegative = Returns to Screening Pathway OPositive = Patient D/C from screening with: official hand-off to Lung/Thoracic Navigator for treatment planning

coordination



Follow-up, Adherence, **Data Collection**

- · Navigator enters/requests order from clinician for appropriate follow-up CT
 - ■LungRADS 1, 2 = LCS Presentive Case LDCT
 - *LongRADS 3, 4A, 4B, 4X = LCS Interior Diagnostic LDCT (71250)
- · Consider allowing navigator to order all follow up exams in advance)
- Data Collection & Management
- **■**ACR registry
- Screening Adherence.
 - ■Past due and follow-ups
- . Billing Issues & Resolution





Wellness & Survivorship

- Tobacco Cenation
- *Survivorship Program
- *Wellnew Program

MY LUNG SCREENING JOURNEY & EXPERIENCE

Wellstar Health System

- 11 hospitals
- 26 imaging centers (screened at 19)
- 9 urgent care centers
- 5 thoracic lung clinics with dedicated MDC team
- 665 lung cancer cases treated in 2022
 - 34,035 total screening exams completed
 - 11,940 unique participants
 - 409 lung cancers (1:29)
 - 84 detected via screening in 2022 (13% of total)
 - 53 ancillary cancers
 - ~600 calls a month
 - ~660 screenings a month (Lowest 542, highest 818)
 - ~10% no show rate
 - 3% biopsy rate
 - ~70% adherence rate

2023 Screenings Scheduled

- 1,8,17 = January-March (209 baselines)
- 6,567 Total patients scheduled for 2023
- On target to complete 9,500 screenings for 2023

THE WELLSTAR PROCESS (PATIENT CENTERED DESIGN)

If you make it EASY, clinicians will refer & patients will return!

LUNG CANCER SCREENING

- Orders routed to program
- Streamlined scheduling & precertification
- Dedicated phone line for intake
- All exams routed to result coordinators for review & disposition
- Results & follow-up recommendation communicated to patient and ordering clinician via program
- All LungRADS 1,2,3 = direct send. All others go through prompt clinical review process
- Concerning cases are fast tracked to MDC clinic by screening navigator
- Screening & outcome data tracked since program inception

- Dedicated physician review team. Having a Bat line is an essential! (Basically, navigator has cell number with understanding she/he can reach out anytime to any physician for questions or guidance regarding a case.)
- Most significant contributor to program success...
 Program <u>OWNS</u> the nodule management process. <u>ALL</u> follow-up exams are ordered and scheduled through program

INCIDENTAL LUNG NODULES

- All notification letters direct patient with a call to action to nodule program for ordering & scheduling
- Nodule program built with autonomy to order and scheduling follow up exam


I know what you are thinking!

No way we could do that here. We don't...



We will not move the needle screening only a few hundred cases a month

We must do better. Think outside the box. Think innovatively.



Homework assignment: See **General Magic**

Lessons Learned from General Magic AND my experience...

- •Having an idea is not good enough must plan and execute
- •Understand your customer and their needs
- •The boring stuff is important
- Set expectations for every step along the way
- •Release early, iterate often (Basically, stop waiting and improve as you go)
- •Know what's going on around you
- •Don't give up, believe in your vision
- Dream big without limitations

Go build your legacy!

THANK YOU

Contact Information:

Email: vickie.beckler@gmail.com

vickie.beckler@astrazeneca.com

Cell: 770-312-3482

